Table of Contents
- Strategy vs. Roadmap: Don’t Confuse Them
- Setting an AI Vision That Survives Contact With Operations
- The Three-Horizon Framework for Pharma AI
- Building the Capability Foundation
- Portfolio Construction: Choosing What to Pursue
- Governance That Doesn’t Slow You Down
- Milestones, Gates, and Honest Course Correction
- References
Executive Summary
Pharma executives are increasingly asked to articulate an AI strategy. Most of what gets produced is closer to a wish list than a strategy — a list of use cases organized by function, without a clear theory of how the organization will build durable capability. A roadmap, by contrast, is the implementation plan that makes the strategy real.
This article lays out a practical structure for moving from strategic intent to operational roadmap. We cover the difference between strategy and roadmap, a three-horizon framework for sequencing AI investments in regulated environments, the capability foundations that determine whether the roadmap can actually be executed, and a governance approach that keeps strategic intent alive without becoming a bottleneck.
Strategy vs. Roadmap: Don’t Confuse Them
An AI strategy answers the question: where will AI create durable competitive advantage for our organization, and how will we organize ourselves to capture that advantage? An AI roadmap answers a different question: what specific things will we do, in what order, with what resources, to make the strategy real?
The two are related but not interchangeable. Many organizations have a strategy without a roadmap — broad ambition without a concrete execution plan. Some have a roadmap without a strategy — a list of pilots without a coherent theory of why these and not others. The combination is what distinguishes high-performing AI programs from cargo-cult ones.
If you’re an executive sponsor of an AI program, the most useful diagnostic is to ask: can someone who’s never seen the strategy reconstruct it from the roadmap, and vice versa? If yes, the two are aligned. If not, one of them is incomplete.
Setting an AI Vision That Survives Contact With Operations
The best AI visions in pharma are concrete enough to constrain choices and abstract enough to outlast specific technologies. “We will be a data-driven organization” is too abstract — it doesn’t constrain anything. “We will deploy ChatGPT in five functions” is too tactical — it will be obsolete in eighteen months.
A strong vision sits in the middle. It typically names: a domain of advantage (e.g., “decision quality across the development lifecycle”), a posture (e.g., “human-led, AI-augmented”), and a non-goal (e.g., “we are not building proprietary foundation models”). These three elements together produce a vision that constrains real-world decisions without locking the organization into a specific technology generation.
The Three-Horizon Framework for Pharma AI
Pharma AI roadmaps benefit from a horizon-based structure that distinguishes near-term, medium-term, and long-term ambitions. Each horizon has different risk tolerance, different metrics, and different capabilities required.
| Horizon | Time Frame | Examples | Primary Goal |
|---|---|---|---|
| Horizon 1 | 0-12 months | Document drafting, knowledge search, summarization, scheduling | Build organizational confidence and prove ROI capture |
| Horizon 2 | 12-24 months | Decision support in clinical operations, pharmacovigilance, regulatory writing, quality investigations | Establish validated AI governance for GxP-adjacent workflows |
| Horizon 3 | 24-48 months | Autonomous workflows in well-bounded GxP domains, AI-driven decision systems, integrated multi-agent systems | Position the organization for the next generation of AI-enabled drug development and operations |
The discipline of horizon-based planning is to ensure each horizon is funded and executed concurrently, not sequentially. Treating Horizon 3 as something that starts after Horizon 2 finishes is how organizations fall behind.
Building the Capability Foundation
Most AI strategies underinvest in the capability foundation that determines whether use cases can succeed. The capabilities below are required for any pharma AI program to scale beyond pilots.
- AI governance. SOPs, tier classifications, review workflows, validation approaches. Without this, every Tier 2 or Tier 3 use case starts from scratch.
- Data infrastructure. Cleaned, accessible, governed data is the most-cited bottleneck in pharma AI. Investments here pay back across every use case.
- Talent and operating model. Internal capacity to manage AI vendors, validate models, and steward use cases through the lifecycle. Outsourcing all of this is a strategic vulnerability.
- Change management capability. Practiced ability to land AI-enabled changes with affected functions. Most pharma organizations underestimate this.
- Portfolio management. A disciplined way to choose what to pursue, what to pause, and what to retire.
Portfolio Construction: Choosing What to Pursue
A pharma AI portfolio should look like a portfolio — a deliberately constructed mix of investments with different risk profiles, time horizons, and strategic logic. Common portfolio dimensions to balance:
- Risk tier: Mix of Tier 1 (low-risk, productivity), Tier 2 (decision support, GxP-adjacent), Tier 3 (autonomous, validated). Avoid concentrating only at one end of the risk spectrum.
- Function: Spread across R&D, clinical, regulatory, manufacturing, quality, commercial. Single-function concentration creates organizational lopsidedness.
- Build vs. buy: Mix of vendor-provided capability, configured platforms, and internally built solutions where the organization can credibly differentiate.
- Time to value: Mix of fast-payback Horizon 1 use cases and longer-arc Horizon 2 and 3 investments.
Governance That Doesn’t Slow You Down
The biggest concern executives have about AI governance in pharma is that it will slow them down. The biggest concern Quality teams have is that absent governance will land the organization in a Purolea-style warning letter. Both concerns are legitimate and reconcilable.
Effective AI governance in pharma typically has three layers. A small executive steering committee that owns strategy, portfolio, and risk appetite. A working AI governance team that owns SOPs, tier classifications, and validation standards. And use case teams that execute within the governance framework. Decisions flow up and down with clear ownership. None of the three layers is an approval committee — they are accountability structures.
Milestones, Gates, and Honest Course Correction
The single most important roadmap discipline is the willingness to course-correct based on evidence. Most pharma AI roadmaps include rolling milestones that the organization is reluctant to revisit honestly. Use cases that are underperforming get refunded. Use cases that are overperforming don’t get scaled fast enough. The portfolio drifts.
The corrective practice is a quarterly portfolio review with explicit gate decisions: continue, scale, pivot, or sunset. Each decision should be backed by evidence — actual ROI, actual adoption, actual quality outcomes. Use cases that fail to meet their gates twice in a row should default to sunset unless there’s a specific reason to continue.
References
For Further Reading
- AI in Pharma and Life Sciences — Deloitte.
- 2025 Life Sciences Outlook — Deloitte Insights.
- Master Data Management for Life Sciences and Pharmaceuticals Industries — CluedIn.
- AI budgets grow in life sciences — McKinsey & Company.
- State-of-the-Art Data Warehousing in Life Sciences — IntuitionLabs.
- Scaling gen AI in the life sciences industry — McKinsey & Company.
Your perspective matters—join the conversation.